Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 44 articles:
HTML format
Text format



Single Articles


    June 2018
  1. LIDOFSKY A, Holmes JA, Feeney ER, Kruger AJ, et al
    Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection.
    J Infect Dis. 2018 Jun 4. pii: 5032604. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  2. COOPER CL
    Now is the Time to Quickly Eliminate Barriers along the Hepatitis C Cascade of Care.
    J Infect Dis. 2018 Mar 9. pii: 4925219. doi: 10.1093.
    PubMed     Text format    


  3. LAMOURY FMJ, Bajis S, Hajarizadeh B, Marshall AD, et al
    Evaluation of the Xpert(R) HCV Viral Load Fingerstick point-of-care assay.
    J Infect Dis. 2018 Mar 9. pii: 4925218. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. STROUVELLE VP, Braun DL, Vongrad V, Scherrer AU, et al
    No Effect of Pegylated Interferon-alpha on Total Hiv-1 DNA Load in HIV-1/HCV Coinfected Patients.
    J Infect Dis. 2018 Mar 8. pii: 4924783. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018

  5. Erratum: Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2018 Jan 27. pii: 4827080. doi: 10.1093.
    PubMed     Text format    


  6. ROLT A, Le D, Hu Z, Wang AQ, et al
    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. SANAKA S, Kasarala GR, Tillmann HL
    A Downside to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression.
    J Infect Dis. 2018 Jan 21. pii: 4770294. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. REID M, Ma Y, Scherzer R, Price JC, et al
    Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
    J Infect Dis. 2018 Jan 3. pii: 4786614. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  9. PERUMALSWAMI PV, Talal AH
    Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders.
    J Infect Dis. 2017 Dec 26. pii: 4774700. doi: 10.1093.
    PubMed     Text format    


  10. STEPANOVA M, Thompson A, Doyle J, Younossi I, et al
    Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
    J Infect Dis. 2017 Dec 26. pii: 4774699. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  11. ROSENBERG BR, Freije CA, Imanaka N, Chen ST, et al
    Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  14. HEIMER R, Binka M, Koester S, Grund JC, et al
    Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


    April 2017
  16. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  17. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  18. HALLAGER S, Brehm Christensen P, Ladelund S, Rye Clausen M, et al
    Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population - a Danish cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  19. HENGST J, Falk CS, Schlaphoff V, Deterding K, et al
    DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  20. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  21. RODRIGO C, Eltahla AA, Bull RA, Grebely J, et al
    Historical trends in the hepatitis C virus epidemics in North America and Australia.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  22. KOSTADINOVA L, Shive C, Judge C, Zebrowski E, et al
    During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  23. MARKOWITZ M, Deren S, Cleland C, La Mar M, et al
    Chronic hepatitis C infection and the pro-inflammatory effects of injection drug use.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  24. ZEREMSKI M, Dimova RB, Pillardy J, de Jong YP, et al
    Fibrosis Progression in Patients with Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  25. FIERER DS
    The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression of Hepatitis C-infected Patients.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  26. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Text format     Abstract available


    June 2016
  27. CHEN YI MEI SL, Burchell J, Skinner N, Millen R, et al
    Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  28. MOQUEET N, Cooper C, Gill J, Hull M, et al
    Responder Interferon Lambda genotypes are associated with higher risk of liver fibrosis in HIV-Hepatitis C Virus Co-infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  29. SAKIANI S, Koh C, Heller T
    Reply to Tennant and Post.
    J Infect Dis. 2016;213:325-6.
    PubMed     Text format    


  30. MASTRO TD, Morrison CS, Hamilton CD
    Determining Hepatitis C Virus Incidence in Populations: an Important Tool for Epidemic Control.
    J Infect Dis. 2016.
    PubMed     Text format    


  31. PATEL EU, Cox AL, Mehta SH, Boon D, et al
    Hepatitis C IgG antibody avidity as a biomarker to estimate population-level incidence.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2015
  32. SWANSON S, Ma Y, Scherzer R, Huhn G, et al
    Association of HIV, HCV and Liver Fibrosis Severity with the Enhanced Liver Fibrosis Score.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  33. SVAROVSKAIA ES, Gane E, Dvory-Sobol H, Martin R, et al
    L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  34. OLMSTEAD AD
    Digging Deeper into Hepatitis C Virus Outbreaks.
    J Infect Dis. 2015.
    PubMed     Text format    


  35. CAMPO DS, Xia GL, Dimitrova Z, Lin Y, et al
    Accurate genetic detection of hepatitis C virus transmissions in outbreak settings.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  36. MORON-LOPEZ S, Gomez-Mora E, Salgado M, Ouchi D, et al
    Short-term treatment with IFNalpha diminishes expression of HIV-1 and reduces CD4+ T-cell activation in HIV/HCV-coinfected patients on antiretroviral therapy.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  37. WANDRER F, Falk C, John K, Skawran B, et al
    Interferon-mediated cytokine induction determines sustained virus control in chronic HCV infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  38. MARTINI H, Citro A, Martire C, D'Ettorre G, et al
    Apoptotic epitope-specific CD8+ T cells and interferon signaling intersect in chronic hepatitis C virus infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  39. SOULIER A, Poiteau L, Rosa I, Hezode C, et al
    Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis and treatment monitoring.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  40. THURSZ M, Lacombe K
    Breaking down barriers to care in Hepatitis C Virus infection.
    J Infect Dis. 2015.
    PubMed     Text format    


    August 2015
  41. TENNANT E, Post JJ
    The Production of False Positive IgM Antibodies to Hepatitis A in Autoimmune Events.
    J Infect Dis. 2015.
    PubMed     Text format    


    July 2015
  42. SPAAN M, van Oord G, Kreefft K, Hou J, et al
    Immunological analysis during IFN-free therapy for chronic HCV reveals modulation of the NK cell compartment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  43. MCKIBBEN RA, Haberlen SA, Post WS, Brown TT, et al
    Chronic Hepatitis C Virus Infection Is Associated with Subclinical Coronary Atherosclerosis in the Multicenter AIDS Cohort Study (MACS): a Cross-Sectional Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  44. ZHOU N, Hernandez D, Ueland J, Yang X, et al
    NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: